Report suggests broader GI role for fecal transplants

09/2/2013 | Vaccine News Daily

Fecal transplants, which are used to treat recurrent Clostridium difficile infection, could also benefit patients with other gastrointestinal diseases, such as constipation, irritable bowel syndrome and inflammatory bowel disease, according to a report from researchers at Montefiore Medical Center in New York. Researchers said long-term follow-up of one study showed C. diff patients had a 91% primary and 98% secondary cure rate with fecal microbiota transplantation.

View Full Article in:

Vaccine News Daily

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA